Takeda Pharmaceutical
0.0 %
-5.86 %
Yet to be announced
Company Overview
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in gastroenterology; oncology; neuroscience; and rare diseases. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig.
Revenue Sources
Based on the company's financial reports and product portfolio, Takeda's revenue primarily comes from pharmaceutical products and therapies that are permissible under Islamic law. Their main revenue streams come from medications and treatments that serve legitimate medical purposes.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| June 30, 2024 | $1.21t | $1.05t | $30.68b | $59.69b | 2.54% | 5.70% |
| March 31, 2024 | $1.21t | $1.05t | $34.81b | $59.69b | 2.88% | 5.70% |
| Dec. 31, 2023 | $1.11t | $1.11t | $21.79b | $66.57b | 1.96% | 5.99% |
| Sept. 30, 2023 | $1.04t | $1.14t | $46.64b | $46.52b | 4.47% | 4.08% |
The interest expense ratio analysis shows that Takeda's interest expenses consistently represent less than 5% of their total expenses across the analyzed quarters. The company maintains relatively low levels of interest-bearing debt relative to their overall operations.
Operational Ethics
After reviewing available information, there is no evidence of significant ongoing associations with entities involved in human rights violations. While the company operates globally, there are no substantial ties to problematic regimes or entities that would raise concerns from an Islamic finance perspective.
Login to join the discussion